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Background: Dry powder inhalers (DPIs) are inspiratory flow driven and hence flow dependent. 
Most patients with chronic obstructive pulmonary disease (COPD) are elderly and have poor 
lung function. The factors affecting their inspiratory flows through inhalers are unclear.
Objective: To study peak inspiratory flows (PIFs) and their determinants through a DPI in 
COPD patients of varying age and severity.
Methods: Flow-volume spirometry was performed in 93 COPD patients. Maximum PIF rates 
were recorded through an empty Easyhaler® (PIFEH; Orion Corporation, Espoo, Finland), a DPI 
that provides consistent dose delivery at inhalation rates through the inhaler of 28 L/min or 
higher.
Results: The mean PIFEH was 54 L/min (range 26–95 L/min) with a coefficient of variation of 
7%. All but two patients were able to generate a flow of $28 L/min. In a general linear model, 
the independent determinants for PIFEH were age (P = 0.02) and gender (P = 0.01), and forced 
expiratory volume in 1 s (FEV1) expressed as percent predicted was not a significant factor. The 
regression model accounted only for 18% of the variation in PIFEH.
Conclusion: In patients with COPD, age and gender are more important determinants of 
inspiratory flow through DPIs than the degree of expiratory airway obstruction. Most COPD 
patients with varying age and severity are able to generate inspiratory flows through the test 
inhaler that is sufficient for optimal drug delivery to the lower airways.
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Introduction
Chronic obstructive pulmonary disease (COPD) represents a global burden with 
increasing prevalence, morbidity, and mortality.1 Patients with diagnosed COPD are 
preferably treated with inhaled medications on a regular daily basis.1 Adherence and 
the correct use of an inhaler are important for successful treatment.2 Inability to use 
the inhaler correctly may result in failure to get the intended dose of medication to the 
airways. Therefore, knowledge of the requirements for specific inhalers is necessary 
when prescribing inhalation therapy.
The choice of the inhaler device is an important part of the management of patients 
with COPD. Two types of portable inhalers are available: pressurized metered dose 
inhalers (pMDI) and dry powder inhalers (DPI). DPIs are inspiratory flow driven and 
easier to use compared with pMDIs as no coordination is required between actuation 
and inhalation. In contrast to MDIs, DPIs have varying internal resistances, require 
sufficient inspiratory flows, and are consequently dependent, in various degrees, on the 
inspiratory effort of the patient.3,4 Easyhaler® (Orion Corporation, Espoo, Finland) is a International Journal of Chronic Obstructive Pulmonary Disease 2010:5
Table 1 Demography and baseline characteristics of the patients
Variable Result
number of patients 93
sex (female/male) 44/49
Mean age, years (range) 65 (47–84)
smoking history
  Current smokers 48
  exsmokers 44
  nonsmokers 1
Mean pack years (range) 40 (0–110)
FeV1, L (range) 1.5 (0.49–3.30)
FeV1, percent predicted normal (range) 51 (18–96)
FVC, L (range) 3.0 (1.4–5.9)
FVC, percent predicted normal (range) 81 (37–130)
FeV1/FVC (%) 44 (21–69)
Current medication, number of patients (%)
  Inhaled corticosteroids 89 (96)
  Long-acting β2-agonist 68 (73)
  short-acting β2-agonist 63 (68)
  Anticholinergic 60 (65)
  Theophylline 22 (24)
Abbreviations: FeV, forced expiratory volume; FVC, forced vital capacity.
Flow
transducer
Spirometer
Airtight
chamber
Easyhaler®
Figure 1 The easyhaler inhaler connected in series to a pneumotachograph.
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device-metered DPI with a relatively high internal resistance. 
In vitro tests have shown that the dose delivery is consistent 
and accurate starting from a minimum inspiratory flow of 
28 L/min through the inhaler.5,6 Easyhaler containing salbuta-
mol, formoterol, budesonide, or beclometasone dipropionate 
is marketed in a number of countries, drug substances that 
are often prescribed for patients with COPD.
A few studies have assessed the ability of patients with 
COPD to use various inhaler devices.7–10 It appears that 
patients with severe COPD may have problems in achieving 
the minimum required inspiratory flow rate through DPIs to 
get the dose to the airways.8 Many patients with COPD are 
also elderly and may have muscle fatigue. Regardless of the 
absence or presence of disease, a study in the elderly showed 
that their ability to generate sufficiently high inspiratory flows 
through DPIs was clearly compromised.9 The main factors 
that affect inspiratory flows through inhalers in patients with 
COPD, and whether any subgroups not capable of efficient 
use of specific DPIs could be identified are unclear.
The aim of this study was to investigate the peak 
inspiratory flow through the Easyhaler (PIFEH) inhaler in 
patients with COPD of various degrees of airway obstruction 
in order to assess the ability of the patients to effectively use 
the device, and to investigate the determinants of the PIFEH, 
using other lung function variables and demographic factors 
of the patients as explanatory variables.
Materials and methods
A total of 104 consecutive patients with previously diagnosed 
COPD treated at the Skin and Allergy Hospital, Helsinki 
University Central Hospital, were invited to take part in 
the study. A total of 93 patients gave their written informed 
consent. Patients with a current COPD exacerbation were 
not allowed to participate. The patients were allowed to use 
their regular medication on the day of the test. All patients 
had typical respiratory symptoms and fulfilled the physi-
ological criterion for COPD with a postbronchodilator forced 
expiratory volume in 1 s (FEV1)/forced vital capacity ratio 
of less than 70%.1 The majority of patients were current or 
exsmokers. The demography and baseline characteristics of 
the patients are shown in Table 1. The study protocol was 
investigator-initiated and approved by the Ethics committee 
of the Department of Medicine of the Helsinki University 
Central Hospital.
Flow-volume spirometry was performed according to 
ATS/ERS guidelines11 including the recording of native 
peak inspiratory flow (PIF) rate. Maximum PIF rates were 
recorded through an empty Easyhaler (PIFEH) connected 
to a pneumotachograph (Spiromaster MX, Medikro Ltd, 
Kuopio, Finland; Figure 1). The patients were instructed to 
exhale gently (to functional residual capacity) and then to 
inhale as fast and long as possible through the inhaler. They 
practiced this inhalation maneuver three times and   thereafter 
three PIFEH   measurements were recorded consecutively. 
  Spirometry and PIFEH measurements were performed in 
random order to compensate for the possible confounding 
effect of muscle fatigue.
The primary outcome variable of the study was PIFEH. The 
proportion of patients with PIFEH exceeding the minimum 
flow of 28 L/min for effective use of Easyhaler was calculated. 
The reproducibility of PIFEH was estimated with an analysis 
of variance. General linear models were used to investigate 
independent determinants of PIFEH and their regression coef-
ficients, in a linear model of PIFEH = b0 + b1x1 + b2x2 + …International Journal of Chronic Obstructive Pulmonary Disease 2010:5
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Figure 2 The distribution of the peak inspiratory flow through Easyhaler (PIFeh) in 
COPD patients of varying severity (n = 93).
Table 2 The relationship between peak inspiratory flow through 
easyhaler and age, height, weight, and lung function in 93 COPD 
patients
Variable ra P
Age, years −0.30 0.004
height, cm 0.26 0.01
Weight, Kg 0.22 0.03
FeV1, L 0.30 0.004
FeV1, percent predicted 0.11 0.28
PeF, L/s 0.32 0.002
PeF, percent predicted 0.17 0.11
PIF, L/s 0.54 ,0.0001
PIF, percent predicted 0.37 0.0003
Notes: aCorrelation coefficient (Pearson).
Abbreviations: FeV1, forced expiratory volume in 1 s; PEF, peak expiratory flow; 
PIF, peak inspiratory flow.
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Figure 3 The relationship between peak inspiratory flow through Easyhaler (PIFeh) 
and age in COPD patients of varying severity (n = 93). Closed circles = men; open 
circles = women.
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bkxk, where x1…k are the independent variables and b1…k are 
their coefficients.
Results
The mean PIFEH was 54 L/min (range 26–95 L/min) with 
a within-subject coefficient of variation of 7.4% (range 
0.9%–40.7%) in three consecutive inhalations. Ninety-
one of the 93 patients (98%) could generate a PIFEH $ 28 
L/min and a total of 271 inspiratory maneuvers through 
the inhaler out of 279 recorded (97%) showed flow rates 
$28 L/min. The distribution of the PIFEH rates is shown 
in Figure 2.
The relationships between PIFEH and lung function 
data and the patients´ age, height, and weight are shown in 
Table 2. The native PIF had the strongest association with 
PIFEH both in terms of absolute values (L/min) and percent 
predicted normal values (r = 0.54; P , 0.0001 and r = 0.37; 
P = 0.0003, respectively).
The relationship between PIFEH and the patients’ 
age (males and females marked separately) is shown in 
Figure 3. A significant correlation was seen between age 
and PIFEH (P = 0.004). Women had significantly lower PIFEH 
(P = 0.004) than men. PIFEH was also significantly related 
to height and weight although the correlation coefficients 
were small.
The univariate relationships of PIFEH with FEV1 and peak 
expiratory flow rates were statistically significant (r = 0.30; 
P = 0.004 and r = 0.32; P = 0.02, respectively). However, 
FEV1 as percent of predicted normal values, ie, FEV1 adjusted 
for age, gender, and height of the subject, was not signifi-
cantly related to PIFEH as shown in Figure 4.
To construct a model predicting PIFEH, a set of 
  explanatory variables were introduced stepwise. Since all 
lung   function variables showed considerable collinearity 
with their   relationship to PIFEH, FEV1 as percent predicted 
was chosen to represent the level of lung function impair-
ment in the model. Table 3 shows the results of the linear 
regression model for best prediction of PIFEH values. Age 
and gender were   significant predictors of the PIF through the 
inhaler. Other variables introduced to the model thereafter, 
such as FEV1, height, and weight, had insignificant effects. 
The full model, however, explained only 18% of the varia-
tion in PIFEH.
Discussion
Our study found that almost all patients with COPD (91 of 
93 patients) have an inspiratory effort sufficient to generate 
inspiratory flows through the test inhaler that should result 
in therapeutic benefit with a drug-loaded device. The series 
of patients represented a wide variety of disease severity and 
airway obstruction and the results are, therefore, applicable 
to most patients with COPD.International Journal of Chronic Obstructive Pulmonary Disease 2010:5
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Figure 4 The relationship between peak inspiratory flow through Easyhaler (PIFeh) 
and FeV1 percent predicted in COPD patients (n = 93).
Table 3 results of the general linear modela to predict PIFeh in 
93 patients with COPD. For the full model, r2 = 0.18 (P = 0.0014)
Parameter Coefficient Standard  
error
P
Intercept 71.7 13.0 ,0.0001
Age, years −0.34 0.15 0.022
gender
  female −6.89 2.62 0.010
  male 0.00
FeV1, percent predicted 0.089 0.077 0.25
Weight, kg 0.047 0.058 0.42
Notes: ay = b0 + b1x1 + b2x2 + … bkxk, where x1…k are the explanatory parameters and 
b1…k are their regression coefficients; see text for an example.
Abbreviations: FeV1, forced expiratory volume in 1 s; PIFeh, peak inspiratory flow 
through the easyhaler. 
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Previously, data on inspiratory flow characteristics 
through DPIs in COPD patients have been limited. A 
study using Turbuhaler®7 showed that all COPD patients 
were able to generate PIF through the inhaler of 28 L/
min, with a variation similar to that we found (Figure 2). 
However, in vitro tests suggest that optimal dosing with 
this inhaler (Turbuhaler) would require flows of at least 
40–60 L/min.6,12 Although PIF through the inhaler showed 
significant associations with FEV1 in liters and native 
PIF, this study was not aimed to investigate the effect of 
degree of lung function impairment (expressed as FEV1 
percent predicted) or other factors such as age or gender. 
In an other study by Broeders et al8 the inhalation profiles 
through Turbuhaler and Diskus® inhalers were compared 
in asthmatics and COPD patients. In the severe COPD 
group, 7%–19% of the patients showed suboptimal flows 
through the inhalers. They found that PIF through the 
inhaler correlated with other parameters of inspiratory 
capacity like native PIF or maximal inspiratory pressures, 
which is in agreement with our results.   However, the effect 
of other factors such as age or sex were not included in 
their analyses. Janssens et al9 studied inspiratory flow rates 
at different levels of resistance, corresponding to differ-
ent types of DPIs, in elderly COPD patients. This study 
showed that in elderly patients, the ability to generate 
sufficient inspiratory flows across a DPI is compromised, 
but since only patients over 70 years were included, it is 
difficult to draw any conclusions whether age, the degree 
of airway obstruction, or other mechanisms are the main 
determinants for the inspiratory flows. The current study is 
the first specifically designed to clarify the relative impact 
of these factors, as well as the performance of Easyhaler 
in patients with COPD.
The present study included only patients with stable 
  disease, and thus the results may be questioned when the 
inhaler has to be used in situations perceived as constrained.13 
Such situations include worsening of asthma, severe COPD 
in general, and COPD exacerbations. Even though exhalation 
may be severely affected in these conditions, it is known 
that inspiration is much less so.14 A study of the course of 
inhalation profiles during an exacerbation of obstructive lung 
disease also showed that despite minor reductions in PIF dur-
ing the acute phase, all patients were able to generate flows of 
30 L/min or more through the DPIs.15 A study investigating 
patients with COPD of various degrees of airway obstruction 
did not find differences in lung deposition between subjects 
with mild or more severe airway obstruction.16 The current 
study also included a wide variety of disease severity and 
airway obstruction, making the results more applicable to 
most patients with COPD.
It is generally believed that DPIs with low internal 
  resistance are more suitable for patients with more severe air-
way obstruction. However, as the turbulent energy is a product 
of the flow and the inhaler’s resistance, for a set energy level 
needed for de-aggregation of the drug particles, the flow 
required through a low resistance DPI will be higher than 
that of a high-resistance DPI.17 With a high-resistance DPI, 
the inspiratory flow through the inhaler will be   determined 
mostly by the inhaler’s resistance and is less affected by 
varying airway resistance of the patient, which may result 
in a more consistent dose emission.18 The Easyhaler is an 
example of an inhaler with a relatively high internal resistance 
and consistent dose delivery over a wide range of inspiratory 
flows.6 The observed inspiratory flows observed in the current 
study (Figure 2) are well within these limits, so despite the 
high resistance of the inhaler, the great majority of COPD 
patients were able to achieve sufficient inspiratory flows 
through Easyhaler for optimal drug delivery to the lower International Journal of Chronic Obstructive Pulmonary Disease 2010:5 submit your manuscript | www.dovepress.com
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airways. This finding agrees with a previous study of young 
children with asthma who also showed sufficient inspiratory 
flows through this inhaler.19 Furthermore, a study with pedi-
atric and adult asthmatic patients has confirmed that clinical 
efficacy of salbutamol is maintained even at low inspiratory 
flow rates when using Easyhaler.20
In view of the previous literature, however, several 
  potential factors may limit the ability of COPD patients 
to generate sufficient inspiratory flows through DPIs.8,9 
We found significant associations with age and gender 
(Figure 3) which have not been specifically reported 
  earlier, although problems with inspiratory flows in elderly 
patients have been shown to be common.9 The results in 
Figure 4 slightly contradict with those of Broeders et al8 
who found suboptimal inspiratory flows more common in 
severe COPD patients with a mean FEV1 of 34% predicted. 
However, they did not analyze the effect of FEV1 as a con-
tinuous variable as in the present study. We constructed a 
  multivariate model to predict PIFEH to clarify these fac-
tors and their relative importance, and to better identify 
patients with increased risk of insufficient inspiratory 
flows through the DPI.   Factors that are generally available 
when treating the patients, ie, age, gender, height, weight, 
and lung   function, were entered into the regression analy-
sis. According to the model (Table 3), as an example, a 
70-year-old female patient with FEV1 of 30% predicted 
and height of 160 cm should have PIFEH of 71.7 – 0.34 
× 70 – 6.89 + 0.089 × 30 + 0.047 × 160 = 51.2 L/min. 
The regression analysis showed that age and gender had 
independent effects on PIFEH and were more important 
than the degree of airway obstruction (expressed as FEV1 
percent predicted), which did not have a significant effect 
in the model. The low coefficient of determination suggests 
that additional physiological factors than those measured 
in this study should be considered to accurately predict 
PIF through inhalers. Such factors might include more 
direct measurements of inspiratory muscle performance or 
  maximum inspiratory pressures.8 However, such data are 
seldom available when treating patients in clinical practice. 
The coefficient of determination was also too low for our 
model to be useful for clinical purposes. Therefore, it is 
advisable to check PIFs through the inhaler individually,17 
especially in elderly patients with COPD, and whenever 
found unsatisfactory, alternative routes for drug admin-
istration should be considered, such as jet nebulizers or 
other flow-independent aerosol delivery systems.
The current results are mainly explained by the general 
physiological determinants of inspiratory flows.   Maximum 
inspiratory flows are dependent on the inspiratory   pressure 
generated by the inspiratory muscles. Since during 
  inspiration, pleural pressure is always subatmospheric and 
lower than bronchial pressure, airflow limitation does not 
occur, although increased airway resistance in patients 
with obstructive pulmonary diseases may have a minor 
effect on flow rates. Accordingly, maximum inspiratory 
flows in COPD patients are significantly less affected than 
  expiratory flows.21 Potential factors decreasing inspiratory 
muscle   performance in COPD patients include aging,22 
malnutrition, and hyperinflation,23 although in the latter 
factor, adaptive mechanisms may partly restore the force 
generating   capacity of the respiratory muscles. The gender-
related difference in maximum inspiratory flows has been 
previously shown in healthy subjects,22 but not in patients 
with COPD or in relation to PIF through inhalers. This 
difference has been attributed to the overall better strength 
of the skeletal muscles in men, due to hormonal or genetic 
differences.22
Conclusion
We conclude that age and gender in COPD patients are more 
important determinants of inspiratory flow through DPIs than 
the degree of expiratory airway obstruction. Most COPD 
patients with varying age and severity are able to generate 
inspiratory flows through Easyhaler that is sufficient for 
optimal drug delivery to the lower airways.
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